The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems? (ECTAug)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2009 by University of Iowa.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
University of Iowa
ClinicalTrials.gov Identifier:
NCT00988663
First received: October 1, 2009
Last updated: NA
Last verified: October 2009
History: No changes posted

October 1, 2009
October 1, 2009
November 2009
November 2011   (final data collection date for primary outcome measure)
Assessment of whether Memantine protects memory and cognitive impairment caused by ECT. [ Time Frame: 6 to 8 weeks ] [ Designated as safety issue: Yes ]
Same as current
No Changes Posted
Whether memantine will improve response of Depression to Electroconvulsive therapy. [ Time Frame: 6-8 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?
Memantine Augmentation of Electroconvulsive Therapy in Patients With Major Depression

The purpose of this study is to determine whether memantine will enhance the therapeutic of effect on depression and prevent memory and other cognitive problems caused by ECT.

Patients will be assigned randomly either to a treatment group or a placebo groups. All patients in both groups will be receiving standard ECT. The treatment group will receive memantine. All patients will be given a battery of cognitive tests and test of depression before ECT treatments start, after the 6th ECT treatment and after the completions of ECT. An analysis will be performed to see if memantine causes any impact on the response to ECT and prevents memory and cognitive impairment.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Major Depressive Disorder
  • Drug: memantine
    patient will receive 5mg daily for 7day then 10 mgm daily
    Other Name: Namenda
  • Drug: Placebo
    will give placebo that looks like memantine
  • Active Comparator: Memantine arm
    Patient receiving ECT and Memantine
    Intervention: Drug: memantine
  • Placebo Comparator: placebo
    25 patients receiving ECT will will receive placebo
    Interventions:
    • Drug: memantine
    • Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
50
May 2012
November 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Meets criteria for Major Depressive disorder

Exclusion Criteria:

  • Neurological disease
  • Mental retardation
  • Seizure disorder
Both
18 Years to 65 Years
Yes
Contact: Jerry L. Lewis, MD 319-384 5630 jerry-lewis@uiowa.edu
Contact: Laurie M McCormick, MD 319-384-7136 laurie-mccormick@uiowa.edu
United States
 
NCT00988663
Memantine ECT trial
Yes
Jerry Lewis MD, professor of psychiatry, Univery of Iowa Hospitals and Clinics
University of Iowa
Not Provided
Principal Investigator: Jerry L Lewis, MD University of Iowa Hospitals and Clinic
University of Iowa
October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP